Go to deals
Healthcare

Väsby Läkargrupp has been acquired by Doktor.se

The shareholders of Väsby Läkargrupp have sold the company to Doktor.se.

Väsby Läkargrupp is a healthcare provider offering primary care, occupational health care and vaccinations through a clinic located in Upplands Väsby in Sweden. The company was founded in 1987 and has approximately 45 employees.

Doktor.se is a digital healthcare and technology company offering digital triage and treatment through its digital healthcare platform as well as through physical clinics in Sweden. The company was founded in 2016 and is one of Sweden’s leading digital healthcare providers.

Oaklins’ team in Sweden acted as financial advisor to the sellers in this transaction.

Parties

Talk to the deal team

Anders Ingler

Senior Advisor
Stockholm, Sweden
Oaklins Sweden

Lars Gustafsson

Partner
Stockholm, Sweden
Oaklins Sweden

Related deals

Instituto Sanitas and Chemopharma have been acquired by Laboratorios Saval
Healthcare

Instituto Sanitas and Chemopharma have been acquired by Laboratorios Saval

Instituto Sanitas and Chemopharma, leading pharmaceutical laboratories in Chile, have been acquired by Laboratorios Saval S.A., a prominent pharmaceutical company based in Chile with a regional presence across Latin America. The transaction strengthens Laboratorios Saval’s growth strategy and supports its expansion in the affordable medicines segment.

Learn more
Rare Patient Voice has been acquired by Konovo
Healthcare | TMT

Rare Patient Voice has been acquired by Konovo

Rare Patient Voice has been acquired by Konovo, a technology-first healthcare intelligence company backed by Fraser Healthcare Partners.

Learn more
Lindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland
Healthcare

Lindenhofgruppe has sold its majority stake in LabPoint to Affidea Switzerland

LabPoint Medical Laboratories AG has been acquired by Affidea Switzerland AG. Through the transaction, Lindenhofgruppe AG gains a strong strategic partner to support the further development of LabPoint and will remain a shareholder with a reduced stake, continuing as a key customer of the company. It lays the foundation for LabPoint’s sustainable development under a new anchor shareholder, with the aim of further strengthening and selectively expanding its position in laboratory diagnostics.

Learn more